WO2016093613A2 - Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma - Google Patents

Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma Download PDF

Info

Publication number
WO2016093613A2
WO2016093613A2 PCT/KR2015/013441 KR2015013441W WO2016093613A2 WO 2016093613 A2 WO2016093613 A2 WO 2016093613A2 KR 2015013441 W KR2015013441 W KR 2015013441W WO 2016093613 A2 WO2016093613 A2 WO 2016093613A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight loss
weight
extract
abnormal weight
composition
Prior art date
Application number
PCT/KR2015/013441
Other languages
English (en)
Korean (ko)
Other versions
WO2016093613A3 (fr
Inventor
마진열
김애영
임민주
오유창
정윤희
Original Assignee
한국한의학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국한의학연구원 filed Critical 한국한의학연구원
Publication of WO2016093613A2 publication Critical patent/WO2016093613A2/fr
Publication of WO2016093613A3 publication Critical patent/WO2016093613A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon

Definitions

  • the present invention relates to a composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract, comprising a dermis extract or a fraction thereof.
  • Body weight is maintained at the proper level when nutrition and energy consumption are balanced. Therefore, if the weight is not eaten due to lack of appetite, or if the energy is excessively consumed even if the meal is sufficient, the weight is reduced when it is not absorbed properly even if a lot is eaten (Park, Young-Kyu, Health after Middle Age No. 11, 1997). Weight loss in healthy people may be a prognostic sign of serious illness, so a medical assessment is needed. In particular, care should be taken because the weight loss of the elderly increases the risk of premature mortality and disability, even if there is a conventional disease.
  • Abnormal weight loss is the name of a disease classified under the World Health Organization (WHO) International Classification of Diseases, R63.4, and includes Involuntary Weight Loss or Unexplained weight loss. It is used in a similar sense. Payne, C et al. Defined abnormal weight loss as a loss of 10% of body weight within 6 months or 5% of body weight in the last month (Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane database of systematic reviews 1, 2012.01).
  • WHO World Health Organization
  • the causes of abnormal weight loss include psychiatric diseases 20-30%, malignant tumors 20%, gastrointestinal diseases 10%, endocrine disorders such as hyperthyroidism or diabetes and 10-15%. A study has reported that no specific cause can be found in% (Park, Young-Kyu, 1997). In addition, a study of Alzheimer's patients found that 22% of patients experienced abnormal weight loss (White et al., 1998). Other causes of abnormal weight loss include AIDS (Mangili, A et al., Clinical infectious diseases 42 (6): 836-42, 2006), chronic obstructive pulmonary disease (Itoh, M et al., Nutrients 5 (4)). : 1316-35, 2013), dementia (Massompoor SM, Shiraz E-Medical Journal 5 (2), 2004), pernicious anemia, kidney failure and tuberculosis have been reported.
  • AIDS Mali, A et al., Clinical infectious diseases 42 (6): 836-42, 2006
  • chronic obstructive pulmonary disease Ito
  • an NF- ⁇ B inhibitor in combination with a melanocortin inhibitor can treat anorexia and weight loss associated with infection, inflammatory disease and cancer.
  • Another object of the present invention is to provide a method for preventing or treating abnormal weight loss symptoms, comprising administering the pharmaceutical composition to a subject.
  • Still another object of the present invention is to provide a dietary supplement for preventing or ameliorating abnormal weight loss symptoms, including dermis extract or fractions thereof.
  • Still another object of the present invention is to provide a quasi-drug composition for preventing or ameliorating abnormal weight loss symptoms, including dermis extract or fractions thereof.
  • Another object of the present invention is to provide a feed composition for the prevention or amelioration of abnormal weight loss symptoms, comprising the dermis extract or fractions thereof.
  • the pharmaceutical composition according to the present invention is excellent in the effect of treating abnormal weight loss symptoms by restoring the loss of weight by inhibiting the loss of fat and muscle weight without causing the change in the size and weight of the tumor and the amount of meals. .
  • Figure 1a is a measure of the change in weight (g) of the group (A), (B), (C), (D) in one embodiment of the present invention
  • Figure 1b is a change in the amount of meal (g)
  • Figure 1c Is the tumor size (mm 3 )
  • Figure 1d shows the tumor weight (g) measured.
  • Figure 2a shows the measured weight (g) change except for the tumor weight of the group (A), (B), (C), (D) in another embodiment of the present invention
  • Figure 2b is the body weight (g)
  • Figure 2c shows the weight of the epididymis around the epididymis (g)
  • Figure 2d shows the gastrocnemius weight (g)
  • Figure 2e shows the weight of the heart (g).
  • Figure 3a shows the change in the growth rate (%) of the mouse muscle cell line C2C12 myocytes treated with the tumor cell culture solution treated with dermis extract
  • C shows the C2C12 muscle cells (control) treated with normal culture medium.
  • Figure 3b shows the change in expression level of the cell proliferation inhibitory proteins (p21, CDK2, Cyclin D, LC3) according to the treatment of the dermal extract treated with dermal extract, "N" is C2C12 muscle cells treated with normal culture medium it means.
  • Figure 3c shows the change in the expression of MyH (Myosin Heavy chain), a protein related to muscle cell differentiation according to tumor cell culture treatment treated with dermis extract in the process of inducing differentiation of C2C12 muscle cells to form myotubes for 4 days
  • MyH Myosin Heavy chain
  • Figure 3d is a myocardium differentiation-related protein MyH (Myosin Heavy chain) expression according to the dermal extract treatment after adding the tumor cell culture (CT-26 culture) treated with dermis extract (cultured CT-26) to the formed root canal and cultured for 3 days The amount of change is shown.
  • CT-26 culture tumor cell culture
  • dermis extract cultured CT-26
  • the amount of change is shown.
  • (a) is a group treated with normal differentiation induction medium
  • (b) is treated with tumor cell culture medium only
  • (c) is treated with tumor cell culture medium treated with dermal extract 250 ⁇ g / mL
  • Figure 4a shows the change in mRNA levels of MAFbx, MuRF-1 associated with muscle loss in the mouse muscle following dermal extract administration
  • Figure 4b shows the protein expression changes.
  • (a) shows the results obtained from the mouse which did not induce abnormal weight loss
  • the present invention provides a pharmaceutical composition for the prevention or treatment of abnormal weight loss symptoms, comprising a dermis extract or a fraction thereof.
  • the present inventors confirmed for the first time that the dermis extract suppresses the loss of fat weight and muscle weight in an animal model in which abnormal weight loss is observed, thereby restoring weight loss, thereby having an excellent effect of treating abnormal weight loss symptoms. Accordingly, the pharmaceutical composition of the present invention can effectively treat abnormal weight loss symptoms, in particular, increase compliance with cancer treatment, alleviate side effects accompanying treatment, and improve the quality of life of patients.
  • the dermis extract not only treats the symptoms of abnormal weight loss itself, but also has an effect of suppressing muscle loss that is suspected as a cause thereof.
  • the term "dermis (Citrus Unshiu Peel)” means dried skin of mature fruit of Citrus unshiu Markovich. Aromatic dry place medicine used for gastritis and indigestion. However, it is not known for the treatment of abnormal weight loss symptoms, which was first identified by the present inventors. In the present invention, the dermis may be purchased commercially available, or may be one that is collected or grown in nature.
  • extract means the extract of the dermis.
  • the extract is a low alcohol having 1 (C1) to 4 (C4) carbon atoms, such as water, methanol, ethanol, etc., in volumes of about 5 to 30 times the dry weight, preferably about 10 to 20 times the dry weight.
  • Elution with a polar solvent such as or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10 the extraction temperature is 20 °C to 100 °C, preferably 60 °C to 100 °C, extraction period is about It may be an extract extracted using an extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction, filtration extraction or ultrasonic extraction for 1 hour to 4 days, but may exhibit a prophylactic or therapeutic effect of abnormal weight loss symptoms of the present invention. As long as it is an extract, it is not limited to this, It can contain the extract, the dilution or concentrate of an extract, the dried material obtained by drying an extract, or all these modifiers or purified products.
  • the extract may be included in an amount of 0.01 to 100% by weight, more preferably 1 to 80% by weight, based on the total weight of the pharmaceutical composition, respectively.
  • fraction refers to the result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture comprising several different components.
  • the fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art. Solvent fractionation by treatment of various solvents, ultrafiltration fractionation through passage of ultrafiltration membranes with constant molecular weight cut-off values, and various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) Chromatography), and combinations thereof.
  • Solvent fractionation by treatment of various solvents ultrafiltration fractionation through passage of ultrafiltration membranes with constant molecular weight cut-off values, and various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) Chromatography), and combinations thereof.
  • solvent fractionation by treatment of various solvents was used to obtain a fraction from the extract by treating a predetermined solvent to the extract obtained by extracting the dermis.
  • the kind of solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols; And nonpolar solvents such as hexane, ethyl acetate, chloroform, dichloromethane and the like. These may be used alone or in combination of two or more thereof. In the case of using alcohol in the fractionation solvent, alcohols of C1 to C4 may be preferably used.
  • the fraction may be prepared by fractionating the dermis extract with a solvent selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, hexane, hexane, ethyl acetate, and a mixed solvent thereof.
  • the fraction may be prepared by fractionating the dermis extract with water, hexane, ethyl acetate, or butanol.
  • the fractions may each comprise 0.01 to 100% by weight, more preferably 1 to 80% by weight relative to the total weight of the pharmaceutical composition.
  • the abnormal weight loss symptom means an abnormal weight loss symptom, and may be used in a similar meaning to involuntary weight loss or unexplained weight loss. For example, it may mean that 10% of body weight is lost within 6 months, or 5% of body weight is lost in the last month (Payne, C et al., 2012).
  • the dermis extract or fractions thereof may be to increase reduced body weight, fat, and muscle weight.
  • the dermis extract has an effect of treating abnormal weight loss symptoms by restoring the loss of weight by inhibiting the loss of fat weight and muscle weight in an animal model in which abnormal weight loss is shown.
  • the size and weight of the tumors appeared similar to animal models without dermal extract, and the amount of meal was also similar. These results suggest that the effect of the present invention is not due to anticancer effect or appetite promotion. Therefore, the composition of the present invention can be usefully used even in patients whose dietary amount is not reduced.
  • the abnormal weight loss symptom is any one selected from the group consisting of cancer, gastrointestinal disorders, hyperthyroidism, diabetes, mental illness, Alzheimer's disease, dementia, AIDS, chronic obstructive pulmonary disease (COPD), pernicious anemia, kidney failure, and tuberculosis. It may be by one.
  • the gastrointestinal disease may be selected from the group consisting of malabsorption, inflammatory bowel disease, and gastrointestinal drainage.
  • the mental illness may include depression, anxiety disorder, post-traumatic stress disorder, schizophrenia, manic depression, epilepsy, personality disorder, and delusional disorder. It is well known in the art that abnormal weight loss symptoms are caused by the disease.
  • the pharmaceutical composition may further comprise an anticancer agent.
  • the anticancer agent may be used without limitation as long as it is a medicament used in the art for the treatment of cancer.
  • Non-limiting examples of such anticancer agents include blastine, mitomycin, cisplatin, doxorubicin, etoposide, tamoxifen, camptothecin, inostomycin, or neocarcinostatin.
  • prevention may mean any action that inhibits or delays the onset of abnormal weight loss symptoms by administering to the subject a pharmaceutical composition for preventing or treating abnormal weight loss symptoms according to the present invention. .
  • treatment may mean any action that improves or benefits the symptoms of abnormal weight loss symptoms by administering the composition of the present invention to a subject suspected of developing abnormal weight loss symptoms.
  • the term “improvement” may mean any action that at least reduces the parameters associated with the condition being treated, for example, the extent of symptoms.
  • the pharmaceutical composition for preventing or treating abnormal weight loss symptoms according to the present invention may further include a pharmaceutically acceptable carrier, and may be formulated together with the carrier to provide food, medicine, feed additives, and drinking water additives.
  • a pharmaceutically acceptable carrier may refer to a carrier or diluent that does not interfere with the biological activity and properties of the compound to be administered without stimulating the organism.
  • the kind of the carrier usable in the present invention is not particularly limited, and any carrier can be used as long as it is a conventionally used and pharmaceutically acceptable carrier in the art.
  • Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof.
  • the carrier may be a non-naturally occuring carrier.
  • ком ⁇ онентs such as antioxidants, buffers and / or bacteriostatic agents may be added and used, and diluents, dispersants, surfactants, binders, lubricants, and the like may be additionally added to provide a solution such as an aqueous solution, a suspension, an emulsion, or the like. It may be formulated into a use formulation, pills, capsules, granules or tablets.
  • the mode of administration of the pharmaceutical composition for the prevention or treatment of abnormal weight loss symptoms according to the present invention is not particularly limited, and may be in accordance with methods commonly used in the art.
  • the composition may be administered by oral or parenteral administration.
  • the pharmaceutical composition for preventing, ameliorating or treating the abnormal weight loss symptoms of the present invention may be prepared in various formulations according to a desired administration method.
  • the pharmaceutical composition of the present invention may also be used as a single agent, and may be prepared and used as a complex preparation, further including a drug known to have a recognized therapeutic effect on weight loss symptoms, and may be formulated using a pharmaceutically acceptable carrier or excipient. Thereby to be prepared in unit dose form or incorporated into a multi-dose container.
  • the present invention provides a method for preventing or treating abnormal weight loss symptoms, comprising administering to the individual a pharmaceutical composition for preventing or treating the abnormal weight loss symptoms.
  • a pharmaceutical composition for preventing or treating the abnormal weight loss symptoms comprising administering to the individual a pharmaceutical composition for preventing or treating the abnormal weight loss symptoms.
  • the term "individual" may refer to any animal, including a human, who may or may have an abnormal weight loss condition.
  • the method for preventing or treating the present invention may specifically include administering the composition in a pharmaceutically effective amount to a subject having or at risk of developing abnormal weight loss symptoms.
  • the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, generally in an amount of 0.001 to 1000 mg / kg, preferably 0.05 The amount of to 700 mg / kg, more preferably 0.1 to 600 mg / kg may be administered once to several times daily. However, for the purposes of the present invention, a suitable total daily usage of the composition comprising the extract may be determined by the practitioner within the correct medical judgment and may be administered once or in divided doses.
  • the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health of the patient, It is desirable to apply differently depending on various factors and similar factors well known in the medical field, including sex and diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or co-specific with the specific composition.
  • compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. In consideration of all the above factors, it is important to administer an amount that can achieve the maximum effect in a minimum amount without causing side effects, and can be easily determined by those skilled in the art.
  • the term "administration" refers to introducing the pharmaceutical composition of the present invention to a patient in any suitable manner, the route of administration of the composition of the present invention being oral or parenteral as long as it can reach the target tissue. Administration can be via a variety of routes.
  • the mode of administration of the pharmaceutical composition according to the present invention is not particularly limited, and may be in accordance with methods commonly used in the art.
  • the composition may be administered by oral or parenteral administration.
  • the pharmaceutical compositions according to the invention may be prepared in various formulations depending on the desired mode of administration.
  • the frequency of administration of the composition of the present invention is not particularly limited, but may be administered once a day or several times in divided doses.
  • the present invention provides a dietary supplement for preventing or ameliorating abnormal weight loss symptoms.
  • the dermis Since the dermis has been used for a long time as a natural substance and has been proved to be safe, it can be prepared and consumed in the form of a food that can prevent or improve abnormal weight loss symptoms.
  • Functional food is the same term as food for special health use (FOSHU), and means foods that have high medical effects and medical effects that are processed so that their bioregulatory functions are efficiently displayed in addition to nutrition.
  • the food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. in order to obtain useful effects in preventing or improving abnormal weight loss symptoms.
  • the kind of the food is not particularly limited, and may include all foods in a general sense.
  • foods to which the substance may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, drinks, tea , A drink, an alcoholic beverage, and a vitamin complex.
  • the composition may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the food composition may comprise a food acceptable carrier.
  • the content of the extract included in the food is not particularly limited, but may be included in 0.01 to 100% by weight, more preferably 1 to 80% by weight relative to the total weight of the food composition.
  • the food when it is a beverage, it may be included in a ratio of 1 to 30 g, preferably 3 to 20 g based on 100 ml.
  • the health functional food can be prepared by a method commonly used in the art, and the preparation can be prepared by adding the raw materials and ingredients commonly added in the art.
  • the preparation can be prepared by adding the raw materials and ingredients commonly added in the art.
  • unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug with food as a raw material, can be excellent in portability.
  • the present invention provides a feed composition for the prevention or improvement of abnormal weight loss symptoms.
  • the feed composition may include a feed additive.
  • the feed additive of the present invention corresponds to a feed supplement in the Feed Control Act.
  • feed may refer to any natural or artificial diet, one meal, or the like, or a component of the one meal, for the animal to eat, ingest, and digest.
  • the kind of the feed is not particularly limited, and may be used a feed commonly used in the art.
  • Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.
  • the present invention provides a quasi-drug composition for the prevention or improvement of abnormal weight loss symptoms.
  • the composition of the present invention can be added to the quasi-drug composition for the purpose of preventing or treating abnormal weight loss symptoms.
  • the term "quasi drug” refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide and similar purposes for the purpose of preventing infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases. It may mean an article other than an apparatus, machine or apparatus, and an article which is not an apparatus, machine or apparatus, which is used for the purpose of pharmacologically affecting the structure and function of a human or animal.
  • the quasi-drug may include external skin preparations and personal hygiene products.
  • it may be, but is not limited to, a disinfectant cleaner, a shower foam, a gagreen, a wet tissue, a detergent soap, a hand wash, or an ointment.
  • the composition according to the present invention when used as an quasi-drug additive, the composition may be added as it is, or used together with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the intended use.
  • the extracted dermis extract was filtered using a standard test sieve (150 ⁇ m, Retsch, Han, Germany) and concentrated to dryness in a freeze dryer.
  • the lyophilized dermis extract powder (50 mg) was dissolved in 1 ml of distilled water, filtered through a 0.22 ⁇ m disk filter, and stored at ⁇ 20 ° C. until use.
  • Abnormal weight loss model was performed by subcutaneous injection of CT-26, a mouse colon cancer cell line, 5x10 6 cells into the abdomen in 6 weeks old male balb / c mice (weight: 21.765 ⁇ 1.03 g) to induce tumor weight loss.
  • the tumor grew to an average of 500 mm 3 , and the weight gain of the (B), (C) and (D) groups was insignificant compared to the normal (A) group. Therefore, from the 14th day of the experiment, 0.9% saline (positive control group) or dermis extract prepared in Example 1 was administered orally daily at a dose of 250 mg / kg or 500 mg / kg with a normal diet. Both saline and dermis extracts were administered 0.2 ml.
  • the weight, meal amount, tumor size, and tumor weight were observed at intervals of 3 to 4 days until day 27 for the group in Table 1, and are shown in FIGS. 1A to 1D.
  • Tumor induction Dermal extract administration end) - - (I) + - (All) + + (250mg / kg) (la) + + (500mg / kg)
  • mice (A) which were orally administered normal diet and saline without inoculation of tumors, body weight increased normally by about 9% to 23.66 ⁇ 1.07 g after 14 days.
  • the weight was still increased to 22.01 ⁇ 0.5 g, with little increase despite the increase in tumor size. This is because the weight was reduced rather than the weight of the tumor, it was confirmed that abnormal weight loss symptoms were induced by the inoculation of the tumor.
  • mice that were orally administered with dermis extract at 250 mg / kg (C) or 500 mg / kg (D) every day showed weight loss as shown in (B) until administration.
  • the amount of meal (g / mouse / day), which may be the main cause of weight gain, showed similar values in the (b), (c), and (d) groups as shown in FIG. On day one, the amount of meal in group (d) administered 500 mg / kg dermis extract was decreased.
  • the dermis extract has an effect of increasing only the ideally reduced weight without causing a change in the size and weight of the tumor and a change in the amount of meal.
  • mice of the (A), (B), (C) and (D) groups were sacrificed to perform autopsy, and the body, except the weight, tumor weight, blood and all organs The weight, the weight around the epididymis, the calf posterior gastrocnemius weight, and the heart weight were measured.
  • the normal group (A) is 26.03 ⁇ 1.18g
  • the tumor inoculated (B) is 19.28 ⁇ 1.00g, compared to the normal group by weight Was reduced by about 26%, indicating that abnormal weight loss was induced.
  • the dermal extract 250 mg / kg administration group (C) is 20.96 ⁇ 1.83 g
  • 500 mg / kg administration group (D) 21.80 ⁇ 1.77 g
  • the body weight is restored by about 5% to 10% by dermal extract administration It was confirmed.
  • the carcasses of the normal group were 18.81 ⁇ 0.79 g and the tumors were inoculated (B) 12.69 ⁇ 1.04 g.
  • the weight was reduced by about 35%, confirming that abnormal weight loss was induced.
  • dermal extract 250 mg / kg administered group (C) is 14.29 ⁇ 0.95 g
  • 500 mg / kg administered group (D) is 15.33 ⁇ 0.45 g
  • the body weight is reduced by 20% to 25% by dermal extract administration It was nothing but
  • the weight of the heart is measured, and as shown in Table 5 and FIG. 2E, the weight of the heart is reduced by the tumor (B), whereas the dermis extract is administered (group (C), ( D) it was found to significantly reduce this loss.
  • the dermis extract has the effect of restoring the loss of fat weight and muscle weight by restoring the weight loss without causing the change of tumor size and weight and the amount of meal. First confirmed excellent.
  • Muscle loss is a major cause of abnormal weight loss in cancer patients.
  • FIG. 3c (a) is a group treated with normal differentiation medium, (b) is a group treated with only tumor cell culture medium, (c) a group treated with a tumor cell culture solution treated with 250 ⁇ g / mL dermis extract, (d ) refers to the group treated with the tumor cell culture solution treated with 500 ⁇ g / mL dermis extract.
  • the pharmaceutical composition according to the present invention is excellent in the effect of treating abnormal weight loss symptoms by restoring the loss of weight by inhibiting the loss of fat and muscle weight without causing the change in the size and weight of the tumor and the amount of meals. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne les éléments suivants : une composition pharmaceutique pour prévenir ou traiter la perte de poids anormale, contenant un extrait de pelure de mandarine satsuma ou ses fractions ; et une méthode de prévention ou de traitement de la perte de poids anormale à l'aide de cette composition. L'extrait de pelure de mandarine satsuma permet au corps de récupérer de la perte de poids par l'inhibition de la perte de poids de graisse et de masse musculaire, ce qui permet d'avoir un excellent effet de traitement contre la perte de poids anormale.
PCT/KR2015/013441 2014-12-10 2015-12-09 Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma WO2016093613A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140177695A KR101731859B1 (ko) 2014-12-10 2014-12-10 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물
KR10-2014-0177695 2014-12-10

Publications (2)

Publication Number Publication Date
WO2016093613A2 true WO2016093613A2 (fr) 2016-06-16
WO2016093613A3 WO2016093613A3 (fr) 2016-09-29

Family

ID=56108329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/013441 WO2016093613A2 (fr) 2014-12-10 2015-12-09 Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma

Country Status (2)

Country Link
KR (1) KR101731859B1 (fr)
WO (1) WO2016093613A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109481593A (zh) * 2018-12-29 2019-03-19 黄书德 一种治疗尿毒症、肾衰竭的药物及其制备方法
US11052124B2 (en) * 2018-11-05 2021-07-06 Tc1 Co., Ltd. Method for reducing fat accumulation by using early-harvested citrus reticulata fruit extract

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102496331B1 (ko) 2020-10-21 2023-02-06 선문대학교 산학협력단 진피 추출물을 포함하는 자궁경부암 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040023196A (ko) * 2002-09-11 2004-03-18 백일성 진피, 적복령, 당귀, 조구등, 석창포, 창출, 백지,산조인, 숙지황, 산수유 및 원지를 주성분으로 함유하는치매치료의 의약 조성물
KR100665503B1 (ko) * 2005-01-06 2007-01-09 주식회사 하이폭시 진피 추출물을 포함하는 허혈성질환 및 퇴행성 뇌질환의예방 및 치료를 위한 조성물
KR101229254B1 (ko) * 2009-11-09 2013-02-26 황성연 녹용, 당귀, 산수유, 구기자, 울금, 산약, 진피, 배초향, 천마, 계피, 오미자, 홍삼, 맥문동 및 감귤분말의 추출물을 유효성분으로 포함하는 면역증강 조성물
CN102119775B (zh) * 2011-01-21 2015-04-29 无限极（中国）有限公司 一种陈皮提取物及其制备方法和应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052124B2 (en) * 2018-11-05 2021-07-06 Tc1 Co., Ltd. Method for reducing fat accumulation by using early-harvested citrus reticulata fruit extract
CN109481593A (zh) * 2018-12-29 2019-03-19 黄书德 一种治疗尿毒症、肾衰竭的药物及其制备方法

Also Published As

Publication number Publication date
KR101731859B1 (ko) 2017-05-04
WO2016093613A3 (fr) 2016-09-29
KR20160070912A (ko) 2016-06-21

Similar Documents

Publication Publication Date Title
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2010087577A2 (fr) Utilisation d'extrait de thymus capitatus, d'extrait de satureja hortensis, ou de carvacrol pour traiter des maladies métaboliques
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
KR101908221B1 (ko) 금방동사니 추출물을 포함하는 항비만 조성물
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
WO2017191856A1 (fr) Effet antidiabétique du gypénoside 75
WO2023106777A1 (fr) Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci
WO2019212300A1 (fr) Composition comprenant un extrait d'aster koraiensis nakai ou une fraction de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie de parkinson
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
KR101445966B1 (ko) 백두구 추출물을 포함하는 항비만 조성물
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2021066425A1 (fr) Vésicules extracellulaires dérivées du gingembre et leur utilisation
WO2011019153A2 (fr) Composition pour la prévention ou le traitement de l’arthrite, contenant un extrait d’un mélange médicinal à base de plantes de schisandra chinensis baillon, scutellaria baicalensis et kalopanax pictus nakai en tant qu’ingrédient actif
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc
WO2020071660A1 (fr) Composition anti-âge contenant comme principe actif une souche d'akkermansia muciniphila ou une culture de cette dernière
WO2020004989A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi
WO2023121314A1 (fr) Utilisation d'un extrait de tubercule d'apios americana pour une protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique
WO2021020857A1 (fr) Utilisation d'une composition destinée à la prévention, au soulagement ou au traitement de troubles de perte osseuse, contenant des extraits de reynoutria japonica et de cassiae cortex interior
WO2012108743A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait des graines de pharbitis blanc
WO2020246863A1 (fr) Composition comprenant du chlorhydrate de cudrania comme composant efficace pour soulager, traiter ou prévenir les maladies musculaires, ou améliorer les fonctions musculaires

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15866867

Country of ref document: EP

Kind code of ref document: A2